Drugs / glovadalen
glovadalen
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT07220551 | Oct → Dec 2025 | — | UCB Biopharma SRL | Completed | No outcome recorded |
| Phase 1 | NCT06970301 | Apr 2025 → May 2026 | — | UCB Biopharma SRL | Completed | No outcome recorded |
| Phase 1 | NCT04867642 | Apr 2021 → Feb 2023 | Parkinson disease | UCB Biopharma SRL | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06055985 | Nov 2023 → Mar 2025 | Parkinson disease | UCB Biopharma SRL | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | glovadalen | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06970301 ↗ |
| Known as | Glovadalene | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068015 ↗ |
| Known as | UCB0022 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04867642 ↗ |
| Modality | Small molecule | — CHEMBL6068015 ↗ |
| Route | Oral | “orally administered as tablet” NCT06055985 ↗ |